A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor

Trial Profile

A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs MOR 208 (Primary) ; Idelalisib; Venetoclax
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms COSMOS
  • Sponsors MorphoSys
  • Most Recent Events

    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 19 May 2017 New drug Venetoclax has been added in the study.
    • 01 Apr 2017 Planned number of patients changed from 120 to 240.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top